ZOTA · Zota Health Care LImited · Biotechnology & Drugs
ZOTA · Zota Health Care LImited · Biotechnology & Drugs
As of 05 Nov close
52-week range
30.0% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹174 Cr
Revenue YoY
PAT YoY
-204.2%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.7
P/S (TTM)
6.2
Sector P/E
36.3
Dividend yield
+0.1%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ZOTA (this stock) | Not meaningful (earnings negative over the last 12 months) | 5.7 | -16.9% | -14.9% | 0.39 | +0.1% |
| Sun Pharmaceutical Industries | 38.9 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 76.4 | 20.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 1q
MF
0.37% (0.00pp)
stable
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 29 Jun 2026 | PRAFUL RATILAL VORA | SELL | 780 | ₹10.15 lakh |
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| ZOTA | 2026-08-04 | 219000 | 1 | WEAK | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: Zota Health Care Limited reported strong Q1 FY27 results, with revenue from operations growing 67.6% YoY to INR 17,360 lakhs, driven by expansion of the Davaindia Network and increased consumer engagement. The company added 264 new stores, bringing total store count to 2,825, with 60 lakh customer footfalls during the quarter. Gross profit reached INR 10,756 lakhs, with gross margin improving to 61.96%. Management emphasized disciplined growth, moderating store expansion in Q2 FY27 to focus on productivity and operational efficiency. The company also highlighted investments in subsidiaries like Davaindia Health Mart, KMHP Ventures, and Curexis Ventures to build a diversified healthcare ecosystem. Marketing expenses rose due to brand ambassadorships, including Mahendra Singh Dhoni, but management noted these were necessary for brand awareness. Store-level EBITDA margins for mature stores (over two years old) were 12-15%, with expectations of improvement as newer stores mature. The company expects cash breakeven by Q1 FY28, with EBITDA positivity anticipated from Q2 FY27 onwards. Management also addressed concerns about store economics, noting that newer stores are maturing faster due to improved brand recognition and generic medicine adoption.
The document emphasizes strong revenue growth, improved margins, and strategic investments, with management expressing confidence in future profitability and market expansion.
Sourced from an exchange-filed transcript, dated 20 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Zota Health Care Limited submitted an investor presentation detailing its operations and financial performance for Q1 FY27. The presentation highlighted the expansion of its retail pharmacy chain, Davaindia, which grew to 2,825 stores by June 30, 2026. Management reported a revenue from operations of ₹14,342.33 lakhs for Q1 FY27, with a gross profit margin of 61.96%. The company emphasized its strategic acquisitions, including an 87.78% stake in Everyday Herbal Group, aimed at enhancing its product portfolio and supply chain. The presentation also outlined the company's focus on affordable healthcare solutions, with Davaindia offering generic medicines at significant discounts compared to branded counterparts. Management noted a strong customer base, with 80% repeat customers, and highlighted the importance of chronic therapies in their revenue mix. The document concluded with a commitment to sustainable growth and careful monitoring of new store performance.
Management emphasized growth and strategic initiatives in the presentation.
Sourced from an exchange-filed presentation, dated 13 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Zota Health Care Limited hosted its earnings conference call on May 25, 2026, to discuss financial results for Q4 and FY26. Management reported a significant year marked by the addition of 997 new Davaindia stores, bringing the total to 2,579. The Davaindia retail business contributed approximately 77% of overall revenue, with a notable revenue increase to INR 41,741 lakhs. The company achieved a consolidated revenue of INR 53,865 lakhs, reflecting an 83.86% year-on-year growth. Gross profit rose to INR 32,468 lakhs, with a gross margin of 60.28%. Management highlighted a focus on improving store-level profitability and operational efficiency in the upcoming quarters while maintaining a goal of expanding to over 5,000 Davaindia stores by FY29. The call included discussions on marketing strategies, store performance, and future growth plans, emphasizing a commitment to affordable healthcare in India.
Management emphasized strong growth and strategic initiatives to enhance business performance.
Sourced from an exchange-filed transcript, dated 29 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Zota Health Care Limited submitted an investor presentation detailing its performance for FY26. The company reported consolidated revenue from operations of ₹53,865.75 lakhs, with a gross profit of ₹32,468.90 lakhs. The Davaindia retail pharmacy chain expanded significantly, reaching 2,579 stores, including 1,656 company-owned and 923 franchisee-operated locations. Management highlighted a strong year with an 84% year-on-year revenue growth, driven by the rapid scale-up of Davaindia. EBITDA turned positive at ₹2,597.73 lakhs, reflecting improved operating efficiencies. The presentation also noted a strategic acquisition of an 87.78% stake in Everyday Herbal Group, enhancing product offerings in the over-the-counter segment. Management emphasized a commitment to reaching over 5,000 Davaindia stores by FY29, focusing on profitability and operational efficiencies moving forward. The document included a detailed overview of the company's business model, financial highlights, and future plans.
Management emphasized strong growth and strategic expansion in the investor presentation.
Sourced from an exchange-filed presentation, dated 23 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Zota Healthcare Limited hosted its Q3 FY26 Earnings Conference Call on February 5, 2026, to discuss its operational and financial performance for the quarter ending December 31, 2025. Management reported strong execution, highlighted by the addition of 276 new Davaindia retail pharmacy stores, bringing the total to 2,331. The company completed a INR 350 crore Qualified Institutional Placement (QIP) to enhance its balance sheet and support expansion. Financial highlights included a consolidated revenue of INR 14,295.14 lakhs, a 98.2% year-on-year increase, and a gross profit of INR 8,617.82 lakhs, up 113.9% YoY. Management noted that while operating profit and EBITDA were impacted by higher expenses related to store expansion, they anticipated normalization as new stores mature. The company aims to expand its Davaindia network to over 5,000 stores by March 2029, supported by the QIP proceeds and improving cash flows.
Management emphasized strong growth and strategic expansion initiatives.
Sourced from an exchange-filed transcript, dated 10 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Zota Health Care Limited submitted an investor presentation detailing its performance and strategic initiatives as of Q3FY26. The presentation highlighted a significant increase in revenue from operations, reaching ₹37,548 lakhs, with a gross profit of ₹22,113 lakhs. The company reported a total of 2,331 operational Davaindia stores, marking a growth of 276 stores in the quarter. Management noted a consolidated operating loss of ₹44.11 lakhs, attributed to higher operating expenses from stores under development. The company emphasized its strategic acquisition of a 65.98% stake in Everyday Herbal Group, enhancing its product portfolio in the OTC category. Management expressed confidence in the long-term goal of expanding to over 5,000 Davaindia stores by March 2029, while focusing on unit economics and operational efficiencies. The presentation also outlined the company's commitment to providing affordable healthcare solutions through its retail pharmacy chain.
The presentation conveyed both growth achievements and challenges faced in operational profitability.
Sourced from an exchange-filed presentation, dated 05 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedZota Health Care Limited's FY2025-26 annual report highlights the company's focus on expanding its retail pharmacy network through its Davaindia vertical, achieving EBITDA positivity, and strengthening its balance sheet with a ₹350 crore Qualified Institutional Placement as stated by management. The report emphasizes the company's mission to provide affordable generic medicines, supported by brand ambassadors and new digital initiatives. Strategic priorities include scaling the store network to 5,000+ by FY29, enhancing store-level profitability, and maintaining quality standards while navigating global and domestic economic challenges.
- Expansion of Davaindia retail network with 997 new stores, reaching 2,579 stores across 23 states and 5 union territories.
- Achievement of EBITDA positivity and significant revenue growth driven by increased customer footfalls and operational efficiency.
- Strengthening of balance sheet through a ₹350 crore Qualified Institutional Placement as stated by management and leveraging brand ambassadors for market outreach.
- Strategic initiatives including Davaindia B2C portal, mobile app, All Day Stores, and UGO Generic to diversify distribution channels.
- Commitment to scaling the network to 5,000+ stores by FY29 and deepening store-level profitability while maintaining quality standards.
Key takeaway: Zota Health Care Limited is aggressively expanding its retail pharmacy network through its Davaindia vertical, aiming to scale to 5,000+ stores by FY29 while maintaining a focus on affordability, quality, and operational efficiency in the generics market.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceRecent (last 12 months)
The company failed to file XBRL disclosures for changes in Secretarial Auditor and dividend announcements as required by SEBI Listing Regulations. Additionally, it delayed locking in warrants by over two months, violating SEBI ICDR Regulations 2018, leading to NSE cautioning against future violations.
Routine disclosures
Related-Party Transaction
1 occurrenceRecent (last 12 months)
The company's 23rd and 25th Annual General Meetings approved related party transactions involving payments to Mr. Niral Muktilal Zota and revisions in remuneration for Whole-time Directors, including Mr. Kamlesh Rajanikant Zota, Mr. Himanshu Muktilal Zota, and Mr. Viren Manukant Zota.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
5.93% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).